Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Follow-up from a phase II clinical study has shown that BioMS Medical's proprietary drug candidate MBP8298 delayed disease progression for five years in progressive multiple sclerosis patients with HLA-DR2 or HLA-DR4 immune response genes.
Subscribe to our email newsletter
Treatment and follow-up of patients from a phase II clinical study demonstrated that patients in this DR2 and DR4 responder group, who comprise up to 75% of MS patients, had a median time to disease progression of 78 months compared to 18 months for patients who received placebo.
“These results show an unprecedented five-year improvement in time to disease progression in the majority of progressive MS patients,” said Kevin Giese, president and CEO of BioMS Medical. “Pending confirmation of these results in our ongoing international pivotal trial in secondary progressive MS, we anticipate that MBP8298 will represent a novel first in class treatment for MS patients.”
The findings are based on a two-year treatment and five-year follow-on study conducted and analyzed by the University of Alberta and BioMS Medical. The primary objective of the trial was to assess the clinical efficacy of 500mg of MBP8298 administrated intravenously every six months, as measured by the Expanded Disability Status Scale (EDSS).